Cystic Fibrosis

July 6, 2016July 6, 2016

Ibuprofen, Inhaled at High Doses, May Be a Way of Treating Cystic Fibrosis

You have probably heard of ibuprofen, a common drug-store medication to help with headaches or sprained ankles. Ibuprofen is an anti-inflammatory drug, which is also one of the reasons it ... Read more

July 1, 2016July 1, 2016

Cystic Fibrosis Foundation Therapeutics Grants $1.7 Million For Development of New Antimicrobial Drug

Cystic Fibrosis, News

Cystic Fibrosis Foundation Therapeutics (CFFT) based in Maryland, and Alaxia SAS in France, have entered an agreement to help support the first-in-patient clinical trial of ALX-009, an inhaled antimicrobial drug for patients with ... Read more

July 1, 2016July 1, 2016

Intestinal Stem Cells Seen to Predict CF Patients’ Response to Therapy, a Potentially Huge Step Forward

Cystic Fibrosis, News

Researchers at University Medical Center Utrecht, in the Netherlands, succeeded in using intestinal stem cells from cystic fibrosis (CF) patients to predict if patients would respond to a particular drug. The technique ... Read more

June 30, 2016June 30, 2016

Lung Disease, New Inhaled Treatments by Pulmatrix Described in Animated Science Video

Asthma, COPD, Cystic Fibrosis, Idiopathic Pulmonary Fibrosis, News

A life sciences animated video was recently released by Pulmatrix to explain breathing issues experienced by patients with serious lung diseases and to illustrate novel promising therapies developed by the company. The ... Read more

June 29, 2016June 29, 2016

Boomer Esiason CF Ambassador, Jerry Cahill, Celebrates 60th Birthday with ‘Living List’

Cystic Fibrosis, News

Boomer Esiason Foundation (BEF) celebrated Jerry Cahill’s 60th birthday on June 27, by demonstrating that people with cystic fibrosis (CF) can live normal lives with exercise and consistent medical care. Cahill is ... Read more

June 29, 2016June 29, 2016

Phase 1 Trial Data on RNA-based Therapy for CF to Be Presented at NACFC 2016

Cystic Fibrosis, News

ProQR Therapeutics recently announced that new data from an ongoing proof-of-concept clinical study, called PQ-010-002, evaluating the effect of an RNA-based therapy (QR-010) on cystic fibrosis patients, will be presented at the North American Cystic Fibrosis Conference ... Read more

June 28, 2016June 28, 2016

P. aeruginosa Infections in CF Patients Aggravated by Workings of ‘Good’ Bacteria, Study Finds

Cystic Fibrosis, News

Bacteria that normally reside in the lungs, not causing disease, produce a compound that makes harmful bacterial infections with Pseudomonas aeruginosa difficult to fight. These infections can be particularly devastating for people ... Read more

June 27, 2016June 27, 2016

Cost of Cystic Fibrosis Therapy Orkambi too High for Low Benefit, Say U.K.’s NICE

Cystic Fibrosis, News

The U.K.’s National Institute for Health and Care Excellence (NICE) announced that is does not recommend funding a cystic fibrosis (CF) treatment Orkambi through Vertex Pharmaceuticals at this time. In March, ... Read more

June 21, 2016June 21, 2016

AffloVest Receives CE Mark Approval for Use in Europe and Elsewhere

Bronchiectasis, Cystic Fibrosis, News

International Biophysics Corporation, an international-American medical device manufacturer, recently announced that they received CE Mark, and approval from Health Canada and the Australian Therapeutic Goods Administration (TGA), for their product ... Read more

June 20, 2016June 20, 2016

Genetic Mutations Linked to CF in Study, While Others Found to Be Benign

Cystic Fibrosis, News

A large screening of children in California helped to identify and distinguish a number of mutations likely to cause cystic fibrosis (CF) from mutations that are benign. The study, “Benign and Deleterious Cystic Fibrosis Transmembrane Conductance ... Read more